Table 1. Examples of cross-reactive epitopes reported in the literature.
MHC | Initial | Subsequent | Initial | Subsequent | Overlap | Id | SO | SE | Ref. |
H2-Kd | LCMV NP | PV NP | YTVKYPNL | YTVKFPNM | YTVK.PN. | 6/8 | 0.92 | 0.81 | [27] |
H2-Kd | LCMV NP | VV P1 | YTVKYPNL | YNSLYPNV | Y...YPN. | 4/8 | 0.71 | 0.68 | [17] |
H2-Kd | LCMV NP | VV P10 | YTVKYPNL | STLNFNNL | .T....NL | 3/8 | 0.58 | 0.48 | [17] |
H2-Kd | LCMV NP | VV A11R | YTVKYPNL | AIVNYANL | ..V.Y.NL | 4/8 | 0.61 | 0.58 | [28] |
H2-Kd | LCMV NP | VV A11R | AVYNFATC | AIVNYANL | A..N.A.. | 3/8 | 0.61 | 0.45 | [28] |
H2-Kd | LCMV NP | VV A11R | ISHNFCNL | AIVNYANL | ...N..NL | 3/8 | 0.53 | 0.48 | [28] |
H2-Kd | RSV5 M2-82 | RSV M2-71 | SYIGSINNI | EYALGVVGV | .Y....... | 1/9 | 0.46 | 0.36 | [29] |
H2-Kd | CTL agonist (APL) | IGRP206-214 | KYNKANWFL | VYLKTNVFL | .Y.K.N.FL | 5/9 | 0.6 | 0.64 | [30] |
H2-Kd | Dengue 2 NS3-298 | Dengue 3 NS3-299 | GYISTRVEM | GYISTRVGM | GYISTRV.M | 8/9 | 0.9 | 0.92 | [31] |
HLA-A2 | EBV BMLF1-280 | FLU A M1-58 | GLCTLVAML | GILGFVFTL | G....V..L | 3/9 | 0.53 | 0.47 | [32] |
HLA-A2 | EBV BMLF1-280 | FLU A NP-85 | GLCTLVAML | KLGEFYNQM | .L....... | 1/9 | 0.38 | 0.28 | [20] |
HLA-A2 | EBV BMLF1-280 | EBV LMP2 | GLCTLVAML | LLWTLVVLL | .L.TLV..L | 5/9 | 0.62 | 0.59 | [20] |
HLA-A2 | EBV BMLF1-280 | EBV BRLF1 | GLCTLVAML | YVLDHLIVV | ......... | 0/9 | 0.32 | 0.22 | [20] |
HLA-A2 | FLU A NA-231 | HCV NS3-1073 | CVNGSCFTL | CVNGVCWTV | CVNG.C.T. | 6/9 | 0.83 | 0.78 | [33] |
HLA-A2 | FLU A M1-58 | EBV EBNA3A-596 | GILGFVFTL | SVRDRLARL | ........L | 1/9 | 0.38 | 0.29 | [20] |
HLA-A2 | HPV 16 E7-11 | Coronavirus NS2-52 | YMLDLQPET | TMLDIQPED | .MLD.QPE. | 6/9 | 0.79 | 0.76 | [34] |
HLA-A2 | HIV ENV GP-120 | M. tuberculosis | VPTDPNPPEV | VLTDGNPPEV | V.TD.NPPEV | 8/10 | 0.79 | 0.8 | [35] |
HLA-B62 | Dengue 2 NS3-71 | Dengue 3 NS3-71 | DVKKDLISY | SVKKDLISY | .VKKDLISY | 8/9 | 0.92 | 0.9 | [36] |
HLA-A1 | Hantaanvirus (Sin) | Hantaanvirus (Seoul) | ISNQEPLKL | ISNQEPMKL | ISNQEP.KL | 8/9 | 0.97 | 0.93 | [37] |
The columns are as follows: 1) MHC restriction, 2) source pathogen and protein for initial infection, 3) source pathogen and protein for subsequent infection, 4) original epitope of initial infection, 5) cross-reactive epitope for subsequent infection, 6) sequence overlap between the cross-reactive epitopes, 7) sequence identity (Id), 8) observed peptide similarity SO and 9) expected peptide similarity SE (for definitions of SO and SE see the main text) 10) reference to the experimental work. Some infectious agents are indicated with abbreviated names and these are: LCMV: Lymphocytic choriomeningitis virus, PV: Pichinde virus (PV), VV: Vacinia virus, EBV: Epstein-Barr virus, RSV: Respiratory synthical virus, HCV: Hepatitic C virus, and HPV: Human papiloma virus.